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Abstract: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the
genus Betacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the
elderly and persons with underlying morbidities. At present, there are no approved vaccines nor
antiviral therapies available. The detection and quantification of SARS-CoV-2-neutralizing antibodies
plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients,
evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines. To detect
SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at
biosafety level 3, considerably limiting the general use of this test. In the present work, a biosafety
level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV)
has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients.
The neutralization titers in serum of two independently analyzed patient cohorts were available
within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test
(Pearson correlation coefficients of r = 0.929 and r = 0.939, respectively). Most convalescent COVID-19
patients had only low titers of neutralizing antibodies (ND50 < 320). The sera of convalescent
COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein
on their surface, which is homologous to the SARS-CoV-2 spike protein. In summary, we report
a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify
SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals.
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1. Introduction
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus
Betacoronaviruses, emerged in December 2019 in the city of Wuhan in China. SARS-CoV-2 is most closely
related to bat SARS-like coronaviruses, suggesting that this new virus originally was a zoonosis [1–3].
In humans, SARS-CoV-2 is readily transmitted via aerosols or droplets. It infects cells expressing the
human angiotensin-converting enzyme 2 (ACE2), which serves as a cellular receptor and is essential for
viral entry [4,5]. Individuals of any age may be infected with SARS-CoV-2, but the elderly and persons
with underlying morbidities particularly suffer from the disease (COVID-19), which is characterized
by fever, coughing, and respiratory distress [2]. The airborne transmission, as well as the fact that
humans do not possess pre-existing immunity to this virus, allowed SARS-CoV-2 to spread rapidly in
the human population, causing a still ongoing pandemic.
Approved vaccines or antiviral drugs for the treatment of COVID-19 patients are not available
yet. Due to the lack of other treatment options, passive immunization of severely ill patients with the
plasma or serum of convalescent COVID-19 patients has been suggested [6]. The principle idea of this
therapy is that virus-neutralizing antibodies in the serum/plasma of convalescent persons would help
the patient to limit virus replication and to recover from the disease. Indeed, passive immunization is
currently an approved treatment for patients suffering from infection with various other viral pathogens,
including hepatitis A virus, hepatitis B virus, varicella zoster virus, cytomegalovirus, and rabies virus
(post-exposure prophylaxis) [7–9]. In contrast to a vaccine, passive immunization is rapidly available,
thereby representing a promising option to immediately treat severely ill COVID-19 patients.
Apart from passive immunization strategies, several vaccine candidates have been developed
and are currently being evaluated in pre-clinical, as well as in advanced clinical, phases. It is generally
believed that the induction of virus-neutralizing antibodies by vaccination will reduce the likelihood
of (re)infection and development of severe disease, thus serving as a correlate of protection.
Enzyme-linked immunosorbent assays (ELISAs) for the detection of SARS-CoV-2 specific
antibodies have become recently available; however, these assays do not provide any information
about the levels of virus-neutralizing antibody titers. Therefore, a classical virus-neutralizing test with
live SARS-CoV-2 has to be performed under biosafety level 3 conditions. The readout of this test is
based on the virus-induced cytopathic effect, which takes 2 to 3 days to fully develop.
Vesicular stomatitis virus (VSV) is a negative-strand RNA virus which possesses a single type
envelope glycoprotein (G) mediating viral entry. Previous studies have shown that G-deleted VSV
can be complemented in trans with the envelope glycoproteins of even unrelated viruses, including
coronaviruses [5,10–12]. Importantly, pseudotype viruses are susceptible to neutralization by antibodies
directed to the foreign glycoprotein [13]. Since pseudotype viruses are restricted to a single round of
infection, these pseudotype virus neutralization assays do not require enhanced biosafety measures.
Moreover, the VSV genome may be easily manipulated in order to encode for reporter proteins, such as
green fluorescent protein (GFP) and luciferase, which facilitates the detection of infected cells in a
reasonable period of time. In this work, we pseudotyped VSV*∆G(FLuc), a G-deleted VSV encoding
both GFP and firefly luciferase [14], with the SARS-CoV-2 spike protein and used it for the detection of
SARS-CoV-2 neutralizing antibodies in the sera of convalescent COVID-19 patients.
2. Materials and Methods
2.1. Cells and Virus
Vero E6 cells were kindly provided by Christian Drosten/Marcel Müller (Charite, Berlin, Germany)
and maintained in Dulbecco’s minimal essential medium (DMEM; Life Technologies, Zug, Switzerland)
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supplemented with 10% fetal bovine serum (FBS) and non-essential amino acids (Life Technologies).
Baby hamster kidney (BHK-21) cells were obtained from American Type Culture Collection (ATCC®
CCL-10; Manassas, VA, USA) and maintained in Glasgow’s minimal essential medium (GMEM, Life
Technologies) supplemented with 10% FBS. BHK-G43, a transgenic BHK-21 cell clone expressing the
VSV G protein in a regulated manner [15], was maintained in GMEM containing 5% FBS. I1-Hybridoma,
which secrete a VSV-neutralizing antibody directed to the envelope glycoprotein G [16], were purchased
from ATCC® (CRL-2700™) and maintained in minimal essential medium (MEM, Life Technologies)
supplemented with 15% FBS. Human embryo kidney (HEK) 293T cells (ATCC, CRL-3216™) were
cultured using DMEM with 10% FBS.
SARS-CoV-2 (SARS-CoV-2/München-1.1/2020/929) was kindly provided by Christian Drosten
(Charité, Berlin, Germany) propagated on Vero E6 cells. SARS-CoV-2 (virus isolate UKEssen) was
isolated from a patient sample in Essen, Germany.
2.2. Detection of SARS-CoV-2 by RT-qPCR
For the detection of SARS-CoV-2 virus, the Allplex™ SARS-CoV-2 specific RT-qPCR assay (Seegene
(Seoul, Korea)) and the RealStar SARS-CoV-2 RT-PCR Kit (Altona Diagnostic Technologies (ADT),
Hamburg, Germany) were used according to the manufacturers’ instructions. The samples were run
on a CFX96™ real-time thermal cycler (Bio-Rad, Feldkirchen, Germany).
2.3. Collection of Serum/Plasma from Convalescent COVID-19 Patients
Patient cohort 1 samples were derived from 21 convalescent plasma donors. Sera and EDTA-plasma
samples were either collected in 7.5 mL serum gel or K3 EDTA monovettes (Sarstedt, Nümbrecht,
Germany) followed by centrifugation at 2500× g for 10 min. Citrate-plasma samples were collected by
plasmapheresis from convalescent plasma donors as a side product of the collection process. In addition,
serum samples were collected from 4 patients who were still under intensive medical care and included
in this cohort (Table 1). Patient cohort 2 samples were obtained from 13 hospital staff members who
had been tested positive for SARS-CoV-2 (Table 2). Serum samples were collected in 7.5 mL serum
monovettes (Sarstedt, Nümbrecht, Germany) and subsequently processed by centrifugation at 2500× g
for 10 min.
All samples were collected in accordance with the German Act on Medical Devices (MPG guideline
98/79/EC) for the collection of human residual material to evaluate suitability of an in vitro diagnostic
medical device (§24). The need for informed consent and ethical approval was waived since all
materials used were residual from routine laboratory diagnostics.
2.4. ELISA
For detection of SARS-CoV-2 spike subunit 1-specific IgG or IgA, the Euroimmun enzyme-linked
immunosorbent assays (ELISA) were used according to the manufacturer’s instructions (Euroimmun
AG, Lübeck, Germany # EI 2606-9601 G and # EI 2606-9601 A). The Euroimmun ELISA has been
recently validated with respect to specificity and sensitivity using COVID-19 patient sera [17]. Binding
of antigen-specific antibodies was recorded at an optical density of 450 nm (OD450) and then divided
by the OD450 of the calibrator provided with each ELISA kit to minimize inter-assay variation (ratio).
Results of the immunoassay were classified into the three categories: negative (ratio < 0.8), borderline
(ratio > 0.8 to ≤1.1), and positive (ratio > 1.1).
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Table 1. Quantification of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-neutralizing antibodies in sera from convalescent plasma donors
(cohort 1).
Patient No. Age (y) Patient
Status
Disease
Severity
Virus Detection
(RT-PCR)
IgG Ratio IgA Ratio ND50 a
PVND50 b
SARS-CoV-2 SARS-CoV-1 VSV G
1 45
Convalescent Mild-Moderate
+ c 4.2 7.9 64 20 <10 <10
2 64 + 4.7 5.1 92 160 20 160
3 64 + 3.9 5.0 65 160 30 160
4 53 + 1.4 0.7 28 10 <10 <10
5 53 + 1.3 1.3 40 60 <10 <10
6 42 + 2.2 2.0 56 40 40 <10
7 49 + 2.2 4.4 65 160 80 <10
8 49 + 3.9 >8 210 380 50 15
9 49 + 1.7 >9 259 640 40 40
10 34 + 2.7 0.8 46 20 <10 <10
11 48 + 2.0 3.3 46 20 <10 10
12 48 + 1.6 4.7 28 25 <10 <10
13 34 + 7.2 3.3 130 80 <10 <10
14 38 + 1.0 6.8 320 400 40 <10
15 29 n.d. d 1.3 7.4 56 80 80 <10
16 27 + 3.3 >8 210 160 160 <10
17 53 − 2.4 1.3 <10 <10 <10 <10
18 46 + 2.3 2.7 65 100 <10 <10
19 47 + 1.3 0.1 40 40 <10 <10
20 26 + 3.3 4.2 56 55 10 <10
21 26 + 2.7 5.6 92 100 80 <10
22 75
Intensive
medical care
Severe
n.d. 1.9 >9 960 640 640 <10
23 66 + 11.6 >8 1280 1280 640 <10
24 56 n.d. 13 >8 733 480 640 <10
25 59 n.d. 8.8 >9 450 546 560 <10
a Neutralization dose 50% (ND50); b Pseudotype virus neutralization dose 50% (PVND50); c “+”, detected, “-“, not detected; d n.d., not determined.
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Table 2. Quantification of SARS-CoV-2-neutralizing antibodies in sera collected from hospital workers (cohort 2).
Patient No. Age (y) Patient
Status
Disease
Severity
Virus Detection
(RT-PCR)
IgG Ratio IgA Ratio
SARS-CoV-2
ND50 a PVND50 b
1 37
Convalescent
Mild + c 1.3 n.d. d 320 158
2 34 Mild n.d. 1.2 1.8 <20 <20
3 46 Mild + 6.8 6.3 480 257
4 32 Mild − 6.3 4.7 560 588
5 40 Mild + 6.6 >10.3 800 257
6 32 Mild + 5.1 4.8 50 56
7 63 Mild + 13.2 >10.3 2560 2512
8 62 Mild + 4.7 1.5 900 209
9 42 Mild − 5.0 4.6 120 105
10 48 Mild + 2.5 <0.8 <20 <20
11 47 Mild + 5.1 8.7 240 105
12 49 Mild + 3.3 5.9 1920 724
13 63 Mild − 2.5 <0.8 <20 <20
a Neutralization dose 50% (ND50); b Pseudotype virus neutralization dose 50% (PVND50); c “+”, detected, “-“, not detected; d n.d., not determined.
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2.5. Generation of Pseudotype Virus
VSV*∆G(FLuc), a G-deficient VSV encoding GFP and firefly luciferase, has been described
previously [14] and was propagated on transgenic BHK-G43 cells expressing the VSV G protein after
induction by mifepristone [15]. The trans-complemented particles (about 108 focus-forming units per
milliliter (ffu/mL) were stored at −70 ◦C in the presence of 5% FBS. Pseudotype viruses were titrated
on BHK-21 cells in 96-well cell culture plates as described previously [14]. Virus titers ranged from
2500 to 10,000 ffu/mL.
For production of pseudotype virus, BHK-21 or alternatively HEK 293T cells were grown in
10-cm cell culture dishes and transfected with 10 µg of pCG1-SARS-CoV-2 (Wuhan-Hu-1) spike
protein expression plasmid [5] or 10 µg of SARS-CoV-1 (Frankfurt-1) spike protein expression plasmid
pCAGGS-SARS-S [5], both kindly provided by Stefan Pöhlmann (German Primate Center, Göttingen,
Germany). Lipofectamine 2000 (Life Technologies, Zug, Switzerland) was employed as transfection
reagent. At 20 h post-transfection, the cells were washed once with GMEM and subsequently inoculated
for 60 min at 37 ◦C with VSV*∆G(FLuc) using an moi of 5 ffu/cell. The cells were washed twice with
GMEM and subsequently incubated at 37 ◦C with GMEM containing 5% FBS and 10% conditioned
cell culture medium of hybridoma cells secreting the VSV neutralizing monoclonal antibody Mab I1,
which prevents carryover of VSV particles carrying the G protein rather than the CoV-S on their cell
surface. At 20 h pi, the cell culture supernatant was harvested, cell debris removed by low-speed
centrifugation (1000× g, 10 min, 4 ◦C), and the pseudotype viruses stored in aliquots at −70 ◦C.
Taking advantage of the GFP reporter for detection of infected cells, the pseudotype viruses were
titrated on Vero E6 cells, which are highly permissive to SARS-CoV-1 and SARS-CoV-2 [18].
2.6. Pseudotype Virus Neutralization Tests
Convalescent plasma/sera were incubated for 30 min at 56 ◦C in order to inactivate complement
factors. For the pseudotype virus neutralization (PVN) test, twofold serial dilutions of the immune
sera were prepared in DMEM cell culture medium. The diluted sera were added to 96-well cell culture
plates (50 µL/well, quadruplicates for each dilution) and incubated for 60 min at 37 ◦C with pseudotype
virus (50 µL/well containing 200 ffu). Vero E6 cell suspension (100,000 cells/mL was added to the wells
(100 µL/well) and incubated for 16 h at 37 ◦C. The cell culture medium was aspirated and the cells lysed
with 50 µL of luciferase lysis buffer (Promega, Dübendorf, Switzerland). The cell lysate (25 µL) was
transferred to white microtiter plates before 25 µL of firefly luciferase ONE-GloTM substrate (Promega)
was added and luminescence recorded using a GloMax® plate reader (Promega). The reciprocal
antibody dilution causing 50% reduction of the luminescence signal was calculated and expressed as
pseudotype virus neutralization dose 50% (PVND50).
2.7. SARS-CoV-2 Neutralization Test
Patient cohort 1 was analyzed using SARS-CoV-2 (SARS-CoV-2/München-1.1/2020/929), whereas,
for patient cohort 2, SARS-CoV-2 (UKEssen) was utilized. Twofold serial dilutions of heat-inactivated
immune sera/plasma were prepared in quadruplicates in 96-well cell culture plates using DMEM cell
culture medium (50 µL/well). To each well, 50 µL of DMEM containing 200 tissue culture infectious
dose 50% (TCID50) of SARS-CoV-2 were added and incubated for 60 min at 37 ◦C. Subsequently, 100 µL
of Vero E6 cell suspension (100,000 cells/mL in DMEM with 10% FBS) were added to each well and
incubated for 56 h at 37 ◦C. The cells were fixed for 1 h at room temperature with 4% buffered formalin
solution containing 1% crystal violet (Merck, Darmstadt, Germany). Finally, the microtiter plates
were rinsed with deionized water and immune serum-mediated protection from cytopathic effect was
visually assessed. Neutralization doses 50% (ND50) values were calculated according to the Spearman
and Kärber method [19].
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2.8. Statistical Analysis
The Pearson correlation coefficient r and linear regression was calculated using GraphPad Software
(San Diego, CA, USA). Kruskal–Wallis test and Dunns’ multiple comparison test were performed to
statistically analyze the impact of anti-coagulants on neutralizing antibody titers.
2.9. Ethical Permission
All samples used in the study were analyzed after conventional diagnostic tests had been
performed. The study did not include patient´s details and did not result in additional constraints for
the patients. All analyses were carried out in accordance with approved guidelines.
3. Results
In order to determine virus-neutralizing antibody levels in sera collected from convalescent
COVID-19 patients, we employed a biosafety level 1 compliant pseudotype virus neutralization (PVN)
test using VSV*∆G(FLuc), a propagation-incompetent vesicular stomatitis virus (VSV) that lacked
the glycoprotein (G) gene but harbored the reporter genes green fluorescent protein (GFP) and firefly
luciferase (FLuc) instead [14]. VSV*∆G(FLuc) was propagated on VSV G protein expressing cells,
resulting in G protein trans-complemented particles, which were then used to infect cells which
transiently expressed the spike protein of either SARS-CoV-1 or SARS-CoV-2 (Figure 1). The infected
cells, which were maintained in the presence of VSV G neutralizing antibody, produced infectious
pseudotype particles that harbored the corresponding spike protein in the viral envelope. Infection of
Vero E6 cells by pseudotype virus was inhibited by spike-specific neutralizing antibodies and was
quantified taking advantage of the FLuc reporter protein. The serum dilution resulting in 50% reduction
of luciferase reporter activity was calculated and expressed as pseudotype virus neutralization dose
50% (PVND50).
In the sera of convalescent COVID-19 patients, neutralizing antibodies were detected (Table 1,
Figure 2a), which was not the case for a COVID-19 negative patient (Figure 2b). No significant
differences were observed when comparing patient sera with EDTA-plasma (p > 0.9999) or citrate-plasma
(p = 0.5530) or comparing EDTA-plasma with citrate-plasma (p > 0.9999), indicating that the collection
method did not interfere with neutralizing antibody titer estimation (Figure 2c). Testing of 25 patients of
various age (26 to 76 years old), who had recovered from COVID-19 with mild to moderate symptoms,
revealed the presence of neutralizing antibodies with varying titers (Table 1). For comparison, serum
samples were collected from 4 patients who were still under intensive medical care. SARS-CoV-2
spike-specific IgG and IgA antibodies were detected by ELISA in all patient sera, but levels seemed to
vary considerably as indicated by IgG and IgA ratios (Table 1).
The PVND50 values varied considerably among the patients ranging from <10 to 1280 (Table 1).
Interestingly, several patients (patients #8, #9, #14, #16, #22–25) who had high neutralizing antibody
titers also showed high ELISA IgA ratios, although patients #1 and #15 did not. Surprisingly, patients
who were still under intensive medical care belonged to this group of high responders.
Most sera also showed neutralizing activity against pseudotype viruses bearing the SARS-CoV-1
spike protein (Table 1). Although SARS-CoV-1 neutralizing antibody titers were mostly lower than
those directed to SARS-CoV-2, there was a significant correlation between SARS-CoV-1 and SARS-CoV-2
spike specific neutralization titers (Pearson r = 0.7811, p < 0.0001). Since it is unlikely that these patients
had been in contact with SARS-CoV-1 in the past, this inhibitory activity is likely due to cross-reaction
of SARS-CoV-2 specific antibodies with the spike protein of SARS-CoV-1, both spike proteins sharing
about 77% homology based on their primary amino acid sequence.
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Figure 1. Pseudotyping of the vesicular stomatitis virus (VSV)*∆G(FLuc) reporter virus with the
SARS-CoV-2 spike protein. The RNA genome of this virus encodes for the nucleoprotein (N),
the phosphoprotein (P), the matrix protein (M), the green fluorescent protein (GFP), the firefly luciferase
(FLuc), and the large RNA polymerase (L), but lacks the viral glycoprotein (G) gene. Propagation of the
G-deficient VSV*∆G(FLuc) on cells expressing the VSV G protein results in trans-complemented viruses
(G-complemented VSV*∆G(FLuc), depicted in blue), which are used to infect cells transiently expressing
either the SARS-CoV-1 or the SARS-CoV-2 spike protein. In the presence of the VSV-neutralizing
antibody Mab I1 (anti-VSV G), pseudotype VSV*∆G(FLuc) particles bearing the corresponding CoV
spike protein in the envelope (depicted in purple) are released. Infection of Vero E6 cells by these
pseudotype particles is inhibited by spike-specific neutralizing antibodies. The pseudotype virus
infection rate is determined by measuring the FLuc reporter activity in the cell lysates 18 h post-infection.
Image created with BioRender.com.
In order to evaluate the specificity of the PVN test we also investigated whether immune sera
from convalescent COVID-19 patients would neutralize VSV*∆G(FLuc) trans-complemented with the
VSV G protein. Since VSV is endemic in the Americas, European citizen probably have rarely been in
contact with this arthropod-borne virus. As expected, most COVID-19 patients had no neutralizing
antibodies directed to the VSV G antigen (Table 1). However, patients #2 and #3 showed PVND50 values
of 160, indicating that these two persons had been infected once with VSV serotype Indiana. There was
no significant correlation between neutralizing antibody titers to VSV G protein and SARS-CoV-2 spike
protein (Pearson r = −0.0138, p = 0.9478).
All sera of the COVID-19 patient cohorts were also tested at biosafety level 3 with a standard
SARS-CoV-2 neutralization test. With this test, the reciprocal antibody dilution that fully protected 50%
of Vero E6 cells from virus-induced cytopathic effect (CPE) at 56 h post-infection (pi) was determined
(neutralization dose 50%, ND50) (Table 1). Although PVND50 and ND50 values were based on a
completely different readout (luciferase reporter activity vs. CPE), the neutralizing antibody titers
as determined by these two methods correlated very well, as indicated by Pearson r values of 0.929
(Figure 3). In order to evaluate the robustness of the PVN test, a distinct cohort of hospital staff
members who have been tested positive for SARS-CoV-2 by RT-PCR or ELISA was also investigated
(Table 2). The correlation between the PVND50 and ND50 again correlated very well (r = 0.939), also the
PVND50 tends to overestimate the titer in this cohort, as the slope is with 0.686 slightly flatter compared
to the patient cohort (0.955) (Figure 3).
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(ND 50) were determined in the sera from two independent cohorts of individuals that had been tested
positive for SARS-CoV-2 infection by RT-PCR and/or ELISA. (a) Convalescent plasma donors and (b)
cohort of hospital staff members. Line and band indicate slope of linear regression and respective
confidence intervals; r = Pearson correlation coefficient.
4. Discussion
There is evidence from experimental vaccination that neutralizing antibodies protect animals
from SARS-CoV-1 infection and disease [20]. In the absence of any other therapeutic options,
passive immunization using plasma of convalescent COVID-19 patients might represent a promising
and immediately available therapy for the treatment of severely ill COVID-19 patients [21,22].
Similarly, virus-neutralizing antibodies are probably the most important mediators of protection
in vaccinated individuals.
In the present work, we used a VSV pseudotype system to detect and to titrate
SARS-CoV-2-neutralizing serum antibodies from convalescent COVID-19 patients. In contrast to
SARS-CoV-2, which has to be handled at biosafety level 3 (BSL-3), the VSV*∆G(FLuc) vector, which has
been used for pseudotyping, can be handled at BSL-1 conditions, thus being the case in most diagnostic
laboratories. Since the glycoprotein G gene has been deleted from the VSV*∆G(FLuc) genome, the virus
is unable to produce any progeny and thus is restricted to a single cycle of infection. However, due to a
strong expression of the firefly luciferase (FLuc) reporter gene encoded by the viral genome, the PVN test
could be already read 18 h post-infection, which is significantly faster than the 56 h that were required
to read the classical neutralization test with live SARS-CoV-2. We used the FLuc reporter as readout as
it allowed us to easily quantify antibody-mediated inhibition of infection. The FLuc reporter may also
allow high throughput screening of high numbers of sera for the presence of SARS-CoV-2-neutralizing
antibodies if titration is not necessary. Despite faster performance compared to the classical virus
neutralization test, the PVN test did not lack behind the classical virus neutralization test in terms of
sensitivity and specificity.
For the therapy of severely ill COVID-19 patients, plasma is normally collected from convalescent
donors ≥ 14 days after resolution of mild to moderate symptoms [22]. According to an EU
guidance for COVID-19 convalescent plasma collection and transfusion, donor plasma should have
SARS-CoV-2-neutralizing antibodies with ND50 values equal or higher than 320 [23]. In our cohorts of
convalescent patients several patients showed ND50 values below this critical threshold value. It might
be therefore necessary to screen many convalescent sera/plasma before the rare high responders are
found who could serve as appropriate plasma donors. Another important criterion is the amount of
IgA in the donor plasma as this isotype (as well as IgM) can be secreted into the mucosal tissues of
the respiratory tract where SARS-CoV-2 replicates. Interestingly, the majority of patients showing
high neutralizing antibody titers also had high IgA ELISA ratios. Since IgA dimers have been shown
to neutralize influenza viruses efficiently due to their quaternary structure [24], we hypothesize that
spike-specific IgA dimers may be more potent in neutralizing SARS-CoV-2 than IgG. The same might
hold true for IgM pentamers. It is tempting to speculate that the increased valency of IgA and IgM
would lead to improved virus neutralization by mediating enhanced aggregation of virions or bridging
of spikes on individual virions. However, this interesting aspect needs to be verified in future studies.
Unfortunately, both IgA and IgM are not persisting for prolonged time and therefore may not contribute
to long-lasting immunity.
In addition to the testing of potential plasma donors for SARS-CoV-2-neutralizing antibodies,
COVID-19 patients should be tested, as well, before they receive the donor plasma. Our study suggests
that at least some COVID-19 patients may already have high levels of neutralizing antibodies in the
blood. In particular, if the patient is under prolonged intensive medical care treatment, the apparent
symptoms might be immune driven and not due to direct virus-mediated damage to the host [25].
Thus, the timing of the therapy might be critically important for the success of the therapy.
For several viral diseases, such as influenza [26] and measles [27], virus-neutralizing antibodies
are a well-established correlate of protection. In contrast, the role of serum antibodies in the protection
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of humans from SARS-CoV-2 infection is not well understood. Passive transfer of murine serum to
naïve mice protected these animals from SARS-CoV-1 challenge infection, suggesting that neutralizing
antibodies alone may sufficiently control virus replication [20,28]. However, the antibody levels that
would mediate sufficient protection of humans still need to be defined. This aspect is also relevant
given that many SARS-CoV-2 vaccines, which are currently developed, are valued according to the
levels of neutralizing antibodies they induce.
Several convalescent COVID-19 patients showed only low levels of neutralizing serum antibodies.
At present, it is not known whether these neutralizing antibody levels are sufficiently high in order
to protect the convalescent patients from repeated infection with SARS-CoV-2. Moreover, it is not
known how these antibody levels would persist with time or how quickly they will drop. To address
all these important questions, the pseudotype virus neutralization test described in this work will be
very helpful.
5. Conclusions
In the present work, a robust pseudotype virus neutralization test has been developed which
allows the rapid and sensitive quantification of SARS-CoV-2-neutralizing antibodies at biosafety level
1. Since the neutralizing antibody titers produced by the pseudotype virus assay correlated very well
with those produced by a standard SARS-CoV-2 neutralization test which was run at biosafety level 3,
this pseudotype virus assay will be useful to screen human B cell clone supernatants for neutralizing
antibodies, evaluation of recombinant nanobodies, testing of immune sera from convalescent COVID-19
patients, and evaluation of experimental vaccines. All this will contribute to the control of the current
SARS-CoV-2 pandemic.
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